Innovations to acquire

Are you an industrialist open to open innovation?
Are you looking for a new product with high added value?

Discover our technologies, developed by SATT Paris-Saclay and resulting from public research, ready to be deployed in French companies (micro-businesses, SMEs, mid-cap companies, large groups) to increase their competitiveness.

AIRPAD

Automatic real-time optimisation of the cycling parameter of a ventilator in VSAI mode to limit patient-ventilator asynchrony.

20 M

patients per year worldwide receive invasive mechanical ventilation

T3D

Ensuring correct anatomical configuration is essential to meet the needs of the 5 to 10% of patients who experience complications.

21 to 43
M d’€

market for custom-made tracheostomy tubes by 2030

COCAPEC

Producing nanoparticles at reduced cost and with controlled morphology.

€11/g

cost of producing silver nanoparticles on a pilot scale

COCOFIBRES

Co-fibre textile collector for recovering fresh water from environmental or industrial mists.

20%

increase in global water demand by 2040

CTAF

New multi-source, modular powertrain structure offering high power levels.

€5.3 billion

market in 2023

DIONYSOS

Biocontrol solution for the preventive and curative control of downy mildew in vines, suitable for use in organic farming.

trial campaigns conducted in the laboratory, in greenhouses and in the field

EASYRISK

More accurate and accessible regional seismic risk assessment for specific sites for insurers.

$2.5 billion

catastrophe insurance market in 2022

EVAC

New resorbable vaccine adjuvant with better performance than reference adjuvants.

50 to 300%

production of antibodies

GASPARD

Real-time monitoring of pollutants and greenhouse gases.

<10 ppb

LOD – NO detection in ambient air

GYRO

Innovative gene therapy treatment for retinal degeneration.

indications for eye diseases targeted initially

LUCKY

Innovative probiotic to improve the prognosis for animals with cancer.

+50%

dogs over 10 years old develop cancer

MICKEY

Prediction and treatment of rejection risk in kidney transplantation.

40 000

kidney transplants in Europe

MICRODROPMIXER

Accelerate contamination-free analyses in multiple fields (biotechnology, agri-food, cosmetics, etc.).

$2.5 billion

global market for microfluidic components in 2017

MIR

New therapeutic approach based on microRNA for the treatment of intestinal inflammation associated with IBD and other forms of severe intestinal inflammation.

200 000

people affected by IBD, including 10% children